Introduction {#S0001}
============

Ankylosing spondylitis (AS) is a chronic debilitating inflammatory autoimmune disease characterized by arthritis and tendinitis of the spine and peripheral joints. Patients with AS have increased mortality compared to the general population, despite improved management and prognoses in recent decades.[@CIT0001] Cardiovascular disease (CVD) has been confirmed as a crucial cause of mortality in AS patients.[@CIT0002] Rapidly accumulating evidence now verifies that there is a higher prevalence of cardiac pathology (ie, myocardial disease, valvular heart disease) and atherosclerosis in patients with AS.[@CIT0003]--[@CIT0005] Of note, studies have shown that AS-related systemic inflammation plays a vital role in the pathogenesis of CVD.[@CIT0006]--[@CIT0008]

CVD risk factors such as obesity, insulin resistance, lipid disorders, and hypertension constitute a pathophysiological condition called metabolic syndrome (MetS). It is acknowledged that MetS increases the risk of CVD and associated mortality.[@CIT0009] Several studies have documented a higher prevalence of MetS in AS patients than in healthy subjects,[@CIT0010]--[@CIT0013] but the factors leading to that finding are unknown. Given that few relevant studies of this problem have been done on the Chinese mainland, the present investigation was conducted to determine the prevalence of MetS in our Chinese AS patients living in the mainland and the possible determinants of its presence.

Patients and methods {#S0002}
====================

Patients and controls {#S0002-S2001}
---------------------

In this cross-sectional study, 117 AS patients who visited the Department of Rheumatology and Immunology at Guangdong Second Provincial General Hospital, Guangdong, China, from March 2016 and August 2018 were enrolled. The 117 consecutive patients met the modified New York criteria for the classification of AS,[@CIT0014] but were excluded if they were ≤16 years of age or had a history of acute myocardial infarction, stroke, coronary artery bypass, peripheral artery occlusive disease, transient ischemic attacks, or chronic kidney disease. The control group included 117 age- and gender-matched healthy subjects who were selected randomly from the Department of Physical Examination Center of Guangdong Second Provincial General Hospital in 2018.They had no specific chief complaints and no history of CVD. The study was approved by the research ethics committee of Guangdong Second Provincial General Hospital (2018-FSKWZ-010), and all participants gave their informed written consent. Moreover, this study was conducted in accordance with the Declaration of Helsinki.

Classification of MetS {#S0002-S2002}
----------------------

The criteria for MetS used in this study were those recommended by the Chinese Diabetes Society (CDS) in 2013,[@CIT0015] which were modified so as to be more appropriate for the Chinese population. MetS was defined when three or more of the following criteria were met: abdominal obesity (waist circumference (WC) ≥90 cm in men and ≥85 cm in women), fasting blood glucose (FBG) ≥6.1 mmol/L or on drug treatment for elevated glucose, elevated blood pressure (≥130/85 mmHg or on drug treatment for hypertension), fasting blood triglycerides (TG) ≥1.7 mmol/L, and fasting blood high-density lipoprotein cholesterol (HDL-c) \<1.04 mmol/L.

Clinical evaluation and laboratory tests {#S0002-S2003}
----------------------------------------

Demographic characteristics such as age, sex, height, weight, WC, smoking, and alcohol consumption habits were registered in all participants. Body mass index (BMI) was also calculated. According to the latest Chinese overweight/obesity medical nutrition treatment expert consensus (2016),[@CIT0016] overweight is defined as 24 kg/m^2^≤BMI ＜28 kg/m^2^ and obesity is defined as BMI ≥28 kg/m^2^. Hypertension and diabetes mellitus were evaluated. Blood pressure was measured based on the European Society of Hypertension guidelines.[@CIT0017]

Clinical characteristics including disease duration, HLA-B27 status, and medical therapies of AS patients were recorded. The Bath Ankylosing Disease Activity Index (BASDAI)[@CIT0018] and Bath Ankylosing Spondylitis Functional Index (BASFI)[@CIT0019] were further assessed. Additionally, venous blood samples were taken after an overnight fast (of at least 8 h) to measure FBG, total cholesterol (TC), TG, HDL-c, low-density lipoprotein cholesterol (LDL-c), serum uric acid (SUA), erythrocyte sedimentation rate (ESR), and C-reactive protein (CRP).

Statistical analysis {#S0002-S2004}
--------------------

Continuous variables were described as mean values ± standard deviation, and categorical variables were described as frequencies and percentages. The chi-square test or Fisher's exact test was used for categorical variables. For continuous variables, the Student's *t*-test was used for normally distributed values and the Mann--Whitney *U* test was used for non-normally distributed values. To evaluate the predictors of incidental MetS in AS patients, a binary logistical regression model was used and odds ratios (OR) with 95% confidence interval (95% CI) were calculated. The variables with *P*≤ 0.1 in univariate regression analyses were chosen for further backward stepwise regression analyses to identify the independent factors correlated with MetS in AS patients. A *P*\< 0.05 was considered significant, and all statistical analyses were carried out using SPSS software, version 20.0 (IBM Corp., Armonk, NY, USA).

Results {#S0003}
=======

Comparisons between AS patients and controls {#S0003-S2001}
--------------------------------------------

The comparisons of demographic characteristics, blood pressure, and laboratory measurements between AS patients and controls are listed in [Table 1](#T0001){ref-type="table"}. These two groups were similar with regard to age, gender, BMI, overweight/obesity, LDL-c, and SUA. The AS group showed higher systolic blood pressure (119.9 ± 11.5 vs 113.2 ± 12 mmHg; *P \<*0.001), diastolic blood pressure (74.6 ± 7.9 vs 71.2 ± 9.9 mmHg; *P \<*0.001), TC/HDL-c (3.9 ± 0.8 vs 3.5 ± 0.5; *P \<*0.001), and FBG (5.0 ± 1.0 vs 4.9 ± 1.6 mmol/L; *P*= 0.004) and lower TC (4.2 ± 0.9 vs 4.8 ± 0.9 mmol/L; *P \<*0.001), HDL-c (1.1 ± 0.2 vs 1.4 ± 0.3 mmol/L; *P \<*0.001) and TG (1.2 ± 0.9 vs 1.7 ± 2.3 mmol/L; *P \<*0.001) than controls. Finally, the AS patients had a higher prevalence of MetS than controls (19.7% vs 9.4%; *P*= 0.026) using the 2013 CDS criteria.Table 1Comparison of the patients with ankylosing spondylitis and the controlsVariablesAS patients (n= 117)Controls (n= 117)*P*-valueAge (years)35 ± 10.335.4 ± 9.50.726Sex (male/female)97/2092/250.407Metabolic syndrome, *n* (%)23 (19.7)11 (9.4)0.026Overweight/obesity, *n* (%)47 (40.2)41 (35.0)0.418Body mass index (kg/m^2^)22.9 ± 3.922.7 ± 3.00.986Systolic blood pressure (mmHg)119.9 ± 11.5113.2 ± 120.000Diastolic blood pressure (mmHg)74.6 ± 7.971.2 ± 9.90.000Fasting blood glucose (mmol/L)5.0 ± 1.04.9 ± 1.60.004Lipid profile (mmol/L)TC4.2 ± 0.94.8 ± 0.90.000HDL-c1.1 ± 0.21.4 ± 0.30.000Low-density lipoprotein2.4 ± 0.72.6 ± 0.70.134Triglycerides1. 2 ± 0.91.7 ± 2.30.000TC/HDL-c3.9 ± 0.83.5 ± 0.50.000Serum uric acid (µmol/L)380.6 ± 95.1393.5 ± 92.50.336[^1]

Comparison of all MetS subjects {#S0003-S2002}
-------------------------------

[Table 2](#T0002){ref-type="table"} summarizes the characteristics of the MetS in AS patients and the controls. TC (4.6 ± 0.9 vs 5.3±1.6 mmol/L; *P =*0.032) and HDL-c (1.4 ± 0.1 vs 1.6 ± 0.7 mmol/L; *P =*0.002) were lower in AS MetS patients relative to the controls while the ratio of TC/HDL-c (4.4 ± 0.9 vs 3.7 ± 0.6; *P =*0.018) was higher in AS MetS patients compared to the controls. No significant differences were found in age, sex, BMI, obesity, WC, blood pressure, FBG, LDL-c, TG, or SUA between the MetS in AS patients and the controls.Table 2Comparison of metabolic syndrome in ankylosing spondylitis patients and controlsVariablesAS patients (n= 23)Controls (n= 11)*P*-valueAge (years)38.6 ± 9.641 ± 8.90.490Sex (male/female)20/39/21.0Obesity, *n*n  (%)10 (43.5)2 (18.2)0.289Body mass index (kg/m^2^)26.8 ± 424.6 ± 2.40.098WC abnormal, n (%)20 (87.0)9 (81.8)1.0Systolic blood pressure (mmHg)128.1 ± 12.5122.5 ± 17.50.285Diastolic blood pressure (mmHg)78.4 ± 8.285.2 ± 13.70.08Fasting blood glucose (mmol/L)5.8 ± 1.77.3 ± 4.40.772Lipid profile (mmol/L)TC4.6 ± 0.95.3 ± 1.60.032HDL-c1.4 ± 0.11.6 ± 0.70.002Low-density lipoprotein2.7 ± 0.33.1 ± 1.00.186Triglycerides2.1 ± 1.31.9 ± 0.41.0TC/HDL-c4.4 ± 0.93.7 ± 0.60.018Serum uric acid (µmol/L)405.2 ± 81.4434.2 ± 101.20.375[^2]

Comparisons between the AS patients with and without MetS {#S0003-S2003}
---------------------------------------------------------

[Table 3](#T0003){ref-type="table"} compares the MetS AS patients vs non-MetS AS patients. AS patients with MetS showed higher frequencies of hypertension (26.1% vs 3.2%; *P*= 0.001), diabetes (13% vs 1.1%; *P*= 0.024), and overweight/obesity (78.3% vs 31.9%; *P \<*0.001). Moreover, BMI, blood pressure, FBG, TC, TG, and the ratio of TC/HDL-c were significantly higher in AS MetS patients relative to non-MetS patients (all *P \<*0.05). Interestingly, BASFI was lower in AS MetS patients compared with non-MetS patients (9.2 ± 18.3 vs 17.4 ± 22.5; *P*= 0.043). No significant differences were observed in age, gender, smoking, drinking, disease duration, LDL-c, HDL-c, SUA, CRP, ESR, the positivity of HLA-B27, and BASDAI. Furthermore, the prescription rates for tumor necrosis factor inhibitors (TNF-i), disease-modifying anti-rheumatic drugs, non-steroidal anti-inflammatory drugs, and prednisone were also similar in the two groups.Table 3Characteristics of ankylosing spondylitis patients, with and without metabolic syndromeVariablesMetabolic syndrome*P*-valueYes (n= 23)No (n= 94)Age (years)38.6 ± 9.634.2 ± 10.30.068Sex (male/female)20/377/170.790Smoking, n (%)1 (4.3)22 (23.4)0.077Drinking, n (%)1 (4.3)2 (2.1)0.485Disease duration (months)134.8 ± 91.6100.5 ± 83.80.073Hypertension, n (%)6 (26.1)3 (3.2)0.001Diabetes, n (%)3 (13.0)1 (1.1)0.024Overweight/obesity, n (%)18 (78.3)30 (31.9)0.000Body mass index26.8 ± 4.022.0 ± 3.30.000Systolic blood pressure (mmHg)128.1 ± 12.5117.8 ± 10.40.001Diastolic blood pressure (mmHg)78.4 ± 8.273.7 ± 7.60.01Fasting blood glucose (mmol/L)5.8 ± 1.74.8 ± 0.70.000Lipid profile (mmol/L)TC4.6 ± 0.94.1 ± 0.80.015HDL-c1.04 ± 0.11.1 ± 0.30.363Low-density lipoprotein2.7 ± 0.62.4 ± 0.70.054Triglycerides2.1 ± 1.31.0 ± 0.50.000TC/HDL-c4.4 ± 0.93.8 ±0.80.000Serum uric acid (µmol/L)405.2 ±81.4368.3 ± 94.80.089CRP (mg/L)12.1 ± 14.321.2 ± 25.90.106ESR (mm/h)25.6 ± 20.131.8 ± 27.20.405HLA-B27 positivity, n (%)21 (91.3)79 (84.0)0.729BASDAI2.3 ± 2.42.9 ± 2.00.137BASFI9.2 ± 18.317.4 ± 22.50.043Medications, n (%)TNF-i18 (78.3)57 (60.6)0.114DMARDs18 (78.3)62 (66.0)0.255NSAIDs21(91.3)93(100)0.098Prednisone0(0)10(10.6)0.223[^3]

Associated factors of MetS in AS {#S0003-S2004}
--------------------------------

[Table 4](#T0004){ref-type="table"} summarizes the results of the logistic regression analyses. As there were only 0 or 1 patient with histories of smoking, drinking, or prednisone treatment in the MetS-AS group, apart from the components of MetS, those three variables were eliminated from the univariate analyses to avoid selection bias. In the univariate analyses, age, BMI, the ratio of TC/HDL-c, SUA, disease duration, and NSAID usage were identified as being different between the MetS AS patients and the non-MetS AS patients with *P*≤ 0.1, and therefore these variables were included in the multivariate regression analysis. Finally, two important predictors of MetS in AS patients were verified: SUA (OR = 2.385; 95% CI = 1.019--5.582; *P =*0.045) and high BMI (OR = 5.165; 95% CI = 1.935--13.787; *P =*0.001) ([Table 4](#T0004){ref-type="table"}).Table 4Univariate regression analyses and multivariate regression analyses of variables associated with metabolic syndrome in patients with ankylosing spondylitisPredictorsUnivariate regression analysesMultivariate regression analyses*β*OR (95%CI)*P*-value*β*OR (95%CI)*P*-valueAge0.0411.041 (0.996--1.088)0.071\-\--Sex0.3871.472（0.392--5.522）0.567BMI0.3781.459 (1.229--1.733)0.0001.6425.165 (1.935--13.787)0.001TC/HDL-c0.8752.400 (1.348--4.274)0.003------SUA0.0041.004 (0.999--1.009）0.0940.8692.385(1.019--5.582)0.045CRP−0.0240.976 (0.947--1.006)0.117ESR−0.0110.989(0.969--1.010)0.305Disease duration0.0041.004 (0.999--1.009)0.092------BASDAI−0.1490.861 (0.675--1.099)0.229BASFI−0.0230.977 (0.948--1.007)0.137TNF-i0.8492.337 (0.799--6.838)0.121DMARDs0.6201.858 (0.632--5.465)0.260NSAIDs−2.1810.113 (0.010--1.304)0.081------[^4]

Discussion {#S0004}
==========

The present study confirmed that mainland Chinese AS patients had a higher prevalence of MetS than the general population. Furthermore, we verified that SUA and high BMI were independent predictors of MetS in these Chinese AS patients.

According to the 2013 CDS criteria, this study found that MetS occurred in 19.7% of the AS patients as compared with 9.4% of the healthy individuals. Previous studies also investigated the prevalence of MetS in AS patients and found rates of 45.8% in Italy,[@CIT0010] 34.9% in Greece,[@CIT0011] and 27% in Brazil.[@CIT0013] Our study found a lower prevalence of MetS in Chinese AS patients than that indicated in foreign reports. This difference may result from the younger age of the AS patients in our study (35 vs 40--50.5 years) or the different criteria of MetS since the 2013 CDS criteria were developed to specifically define MetS for the Chinese. Different therapeutic strategies, genetic factors, and races should also be considered. However, the results of our study indicating that MetS was more prevalent in AS patients than in the controls was in agreement with previous studies.[@CIT0010]--[@CIT0013]

AS patients in this study had lower HDL-c and TC levels but higher TC/HDL-c ratios than the controls. AS patients with MetS also had lower HDL-c and TC but higher TC/HDL-c ratios than the healthy controls with MetS. HDL-c has anti-inflammatory and anti-atherosclerotic properties.[@CIT0020] Mathieu et al reported that decreased TC and HDL-c occurred in AS patients and that the low HDL-c levels appeared to play a crucial role in developing myocardial infarctions in AS patients.[@CIT0021] Moreover, Toms et al found that TC/HDL-c had a better association with inflammatory biomarkers and CVD risk than TC or HDL-c in patients with rheumatoid arthritis.[@CIT0022] Therefore, we further tested whether TC/HDL-c was an independent predictor of MetS in AS patients. In the univariate regression analyses, TC/HDL-c significantly increased the danger of MetS in AS patients (OR = 2.400; 95% CI = 1.348--4.274; *P*= 0.003). However, this ratio was removed from the analysis after adjustment with other factors. As an index for predicting the cardiac risk, TC/HDL-c in AS patients with MetS has an uncertain role and will need further investigation to establish its usefulness.

In this study, SUA levels showed no difference between MetS and non-MetS in AS patients, which was in keeping with the results of Maia et al[@CIT0013]. Nevertheless, SUA was associated with AS MetS patients under the univariate regression analyses (*P*≤ 0.1). The cut point of SUA in the further multivariate regression analysis was 416.4 μmol/L for men and 356.9 μmol/L for women, which means that hyperuricemia independently increased the risk of MetS in AS patients (OR = 2.385; 95% CI = 1.019--5.582; *P*= 0.045). Lin et al[@CIT0023] reported that hyperuricemia was strongly correlated with the development of MetS in subjects in Taiwan. The possible common mechanisms underlying the development of hyperuricemia and MetS were also identified: endothelial damage via oxidative-redox stress, systemic inflammation, adipokines (such as leptin), unhealthy diets, and lack of physical activity.[@CIT0023] Additionally, studies have demonstrated that people with hyperuricemia had a higher risk of developing hypertension, overweight/obesity, type 2 diabetes mellitus, kidney diseases, and CVD.[@CIT0024] Recently, Zhu et al[@CIT0025] found that without concomitant gout, significant deposition of monosodium urate crystals occurred in the sacroiliac joint of patients with axial spondyloarthropathy and exacerbated the radiographic progression of their disease. Thus, the current evidence suggests that hyperuricemia cannot be ignored in AS patients.

We found that BASDAI, CRP, ESR, and disease duration were not different in the MetS and non-MetS AS patients, which was consistent with both Malesci's[@CIT0010] and Maia's[@CIT0013] reports, while Papadakis et al[@CIT0011] found that MetS AS patients had higher BASDAI (*P*\< 0.05) and longer disease duration (*P*\<0.05). In addition, non-MetS AS patients in our study showed significantly higher BASFI indices than the MetS AS patients (*P*= 0.043), while the univariate regression analyses were not different (*P*= 0.137). Previous studies also showed no difference of BASFI between the two groups,[@CIT0010]--[@CIT0013] and so our results support the idea that BASFI has no bearing on MetS in AS patients.

The stepwise multivariate regression analysis in our study also suggested that high BMI independently increases the prevalence of MetS in AS patients (OR = 5.165; 95% CI = 1.935--13.787; *P*= 0.001). Moreover, high BMI has been reported to be a crucial determinant MetS in rheumatoid arthritis,[@CIT0026] systemic lupus erythematosus,[@CIT0027] and psoriasis.[@CIT0028] The mechanisms for accelerating MetS by high BMI have also been explored: more pro-inflammatory cytokines (including TNF-α and IL-6) and adipokines (such as leptin and adiponectin) are released by fat tissue, which adversely affect MetS.[@CIT0029]

As the present report is the first study concerning the prevalence of MetS in mainland Chinese AS patients, some limitations should be mentioned. First, socioeconomic factors such as educational attainment, field of employment, and poverty level were not taken into account. These factors may also affect the prevalence of MetS. Second, a cross-sectional study design might not be useful to determine causality between AS and presence of MetS. Third, this was a single-center study; thus, its reliability and representativeness were open to question.

Conclusion {#S0005}
==========

This study showed a greater prevalence of MetS in mainland Chinese AS patients than controls. AS patients with hyperuricemia or/and high BMI are more susceptible to MetS. Our study indicates that, beyond traditional CVD risk factors, special attention should be paid to effective control of SUA for preventing MetS in AS patients.
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[^1]: **Abbreviations:** AS, ankylosing spondylitis; TC, total cholesterol; HDL-c, high-density lipoprotein.

[^2]: **Abbreviations:** AS, ankylosing spondylitis;  WC, waist circumference; TC, total cholesterol; HDL-c, high-density lipoprotein.

[^3]: **Abbreviations:** TC, total cholesterol; HDL-c, high-density lipoprotein; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; HLA-B27, human leukocyte antigen-B27; BASDAI, Bath Ankylosing Disease Activity Index; BASFI, Bath Ankylosing Spondylitis Functional Index; TNF-i, tumor necrosis factor inhibitors; DMARDs, disease-modifying anti-rheumatic drugs; NSAIDs, non-steroidal anti-inflammatory drugs.

[^4]: **Abbreviations:** BMI, body mass index; TC, total cholesterol; HDL-c, high-density lipoprotein; SUA, serum uric acid; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; BASDAI, Bath Ankylosing Disease Activity Index; BASFI, Bath Ankylosing Spondylitis Functional Index; TNF-i, tumor necrosis factor inhibitors; DMARDs, disease-modifying anti-rheumatic drugs; NSAIDs, non-steroidal anti-inflammatory drugs.
